HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tsutsumi, M. Articles by Pan, C. Q. Search for Related Content PubMed PubMed Citation Articles by Tsutsumi, M. Articles by Pan, C. Q. Social Bookmarking                What's this?

A Potent and Highly Selective VPAC2 Agonist Enhances Glucose-Induced Insulin Release and Glucose Disposal

A Potential Therapy for Type 2 Diabetes

¹ Department of Metabolic Disorders Research, Pharmaceutical Division, Bayer Corporation, West Haven, Connecticut
² Department of Molecular Technologies, Biotechnology, Bayer Corporation, Berkeley, California

Pituitary adenylate cyclase—activating peptide (PACAP) and vasoactive intestinal peptide (VIP) activate two shared receptors, VPAC1 and VPAC2. Activation of VPAC1 has been implicated in elevating glucose output, whereas activation of VPAC2 may be involved in insulin secretion. A hypothesis that a VPAC2-selective agonist would enhance glucose disposal by stimulating insulin secretion without causing increased hepatic glucose production was tested using a novel selective agonist of VPAC2. This agonist, BAY 55-9837, was generated through site-directed mutagenesis based on sequence alignments of PACAP, VIP, and related analogs. The peptide bound to VPAC2 with a dissociation constant (K_d) of 0.65 nmol/l and displayed >100-fold selectivity over VPAC1. BAY 55-9837 stimulated glucose-dependent insulin secretion in isolated rat and human pancreatic islets, increased insulin synthesis in purified rat islets, and caused a dose-dependent increase in plasma insulin levels in fasted rats, with a half-maximal stimulatory concentration of 3 pmol/kg. Continuous intravenous or subcutaneous infusion of the peptide reduced the glucose area under the curve following an intraperitoneal glucose tolerance test. The peptide had effects on intestinal water retention and mean arterial blood pressure in rats, but only at much higher doses. BAY 55-9837 may be a useful therapy for the treatment of type 2 diabetes.

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				Z.-L. Chu, R. M. Jones, H. He, C. Carroll, V. Gutierrez, A. Lucman, M. Moloney, H. Gao, H. Mondala, D. Bagnol, et al. A Role for {beta}-Cell-Expressed G Protein-Coupled Receptor 119 in Glycemic Control by Enhancing Glucose-Dependent Insulin Release Endocrinology, June 1, 2007; 148(6): 2601 - 2609. [Abstract] [Full Text] [PDF]

				S. S. Qader, J. Jimenez-Feltstrom, M. Ekelund, I. Lundquist, and A. Salehi Expression of islet inducible nitric oxide synthase and inhibition of glucose-stimulated insulin release after long-term lipid infusion in the rat is counteracted by PACAP27 Am J Physiol Endocrinol Metab, May 1, 2007; 292(5): E1447 - E1455. [Abstract] [Full Text] [PDF]

				C. Q. Pan, F. Li, I. Tom, W. Wang, M. Dumas, W. Froland, S. L. Yung, Y. Li, S. Roczniak, T. H. Claus, et al. Engineering Novel VPAC2-Selective Agonists with Improved Stability and Glucose-Lowering Activity in Vivo J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 900 - 906. [Abstract] [Full Text] [PDF]

				B. Ahren, N. Wierup, and F. Sundler Neuropeptides and the Regulation of Islet Function Diabetes, December 1, 2006; 55(Supplement_2): S98 - S107. [Abstract] [Full Text] [PDF]

				D. R. Branch, P. B. Bokaei, D. Sakac, and X.-Z. Ma HIV-1 Proviral Integration Is Blocked by Agonists to the VpPAC2 Neuroendocrine Receptor. Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 1427 - 1427. [Abstract]

				S. Tsunekawa, Y. Miura, N. Yamamoto, Y. Itoh, Y. Ariyoshi, T. Senda, Y. Oiso, and I. Niki Systemic administration of pituitary adenylate cyclase-activating polypeptide maintains beta-cell mass and retards onset of hyperglycaemia in beta-cell-specific calmodulin-overexpressing transgenic mice Eur. J. Endocrinol., May 1, 2005; 152(5): 805 - 811. [Abstract] [Full Text] [PDF]

				L. Akesson, B. Ahren, G. Edgren, and E. Degerman VPAC2-R Mediates the Lipolytic Effects of Pituitary Adenylate Cyclase-Activating Polypeptide/Vasoactive Intestinal Polypeptide in Primary Rat Adipocytes Endocrinology, February 1, 2005; 146(2): 744 - 750. [Abstract] [Full Text] [PDF]

				J.-C. Henquin Pathways in Beta-Cell Stimulus-Secretion Coupling as Targets for Therapeutic Insulin Secretagogues Diabetes, December 1, 2004; 53(suppl_3): S48 - S58. [Abstract] [Full Text] [PDF]

				S. L. Yung, F. Dela Cruz, S. Hamren, J. Zhu, M. Tsutsumi, J. W. Bloom, M. Caudle, S. Roczniak, T. Todd, L. Lemoine, et al. Generation of Highly Selective VPAC2 Receptor Agonists by High Throughput Mutagenesis of Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Peptide J. Biol. Chem., March 14, 2003; 278(12): 10273 - 10281. [Abstract] [Full Text] [PDF]